iPS Cells & Regenerative Medicine– category –
-
ARPA-H Invests $125M in On-Demand RNA Medicine Manufacturing; ArsenalBio Pivots to In Vivo CAR T Cell Therapies for Solid Tumors
The Pharma Letter USA Overview ARPA-H has committed $125 million to five teams developing on-demand manufacturing capabilities for RNA medicines, a strategic investment to enhance rapid pharmaceutical response to future public health cri... -
Fate Therapeutics Initiates Phase 2 RECLAIM-LN Trial for Lupus Nephritis with Off-the-Shelf iPSC-Derived CD19 CAR-T Cell Therapy FT819
Seeking Alpha USA Overview Fate Therapeutics has commenced its Phase 2 RECLAIM-LN trial for lupus nephritis, administering the first patient with its iPSC-derived CD19 CAR-T cell therapy, FT819, in an outpatient setting. This marks a sig... -
August Sees Mixed Fortunes in Gene Therapy: Ultragenyx’s GSDIa Therapy Gets Accelerated Approval, Epicrispr Raises $90M, While REGENXBIO’s RGX-121 Faces Clinical Hold
Vertex AI Search USA Overview August 2026 brought both significant advancements and setbacks in the next-generation therapeutics space. Ultragenyx secured FDA accelerated approval for GENGLYCOS, a gene therapy for GSDIa, offering a new o... -
iPS Cells & Regenerative Medicine Weekly Report August 30, 2026
▼ ▼ ▼ If the infographic makes you want to read the full report, please click the download button below. ▼ ▼ ▼ 📄 Weekly Report August 30, 2026 (PDF) — Download Weekly Report August 30, 2026 (PDF) — DownloadDownload 🎙 Podcast August 30, ... -
Protein Interactions Shed New Light on Autism Causes: Advancing Neurological Disease Understanding
Fierce Biotech USA Overview Research reports that complex protein-protein interactions offer new insights into the fundamental causes of autism spectrum disorder (ASD). This discovery is a critical step towards understanding the intricat... -
Bridging the Data Integrity Gap in Pharmaceutical Quality Control: Ensuring Reliability for Advanced Medicinal Products
European Pharmaceutical Review EU Overview The critical importance of closing the data integrity gap in pharmaceutical quality control has been re-emphasized. For advanced medicinal products like cell and gene therapies, stringent reliab... -
MSD-Moderna Personalized mRNA Neoantigen Combination Adjuvant Therapy Reports Positive Phase III Results in Melanoma
European Pharmaceutical Review USA Overview MSD (Merck) and Moderna's personalized mRNA neoantigen combination adjuvant therapy has announced positive results from its Phase III clinical trial in high-risk melanoma patients. The data sug... -
European Commission Approves Acadia’s Trofinetide as First EU Rett Syndrome Treatment
European Pharmaceutical Review EU Overview The European Commission (EC) has approved Acadia Pharmaceuticals' trofinetide as the first treatment for Rett syndrome in the European Union. This approval represents a landmark advancement, off... -
FDA Approves First Gene Therapy for Glycogen Storage Disease Type Ia (GSDIa), Offering New Option for Patients Aged 8+
Pharmacy Times USA Overview The U.S. FDA has approved the first gene therapy for Glycogen Storage Disease Type Ia (GSDIa), targeting the underlying cause of this rare metabolic disorder in patients aged 8 and older. GSDIa results from a ... -
Decoding Hashimoto’s: Exosomes Emerge as Pivotal for Diagnosis and Therapy
PubMed International Overview A groundbreaking study reveals the critical role of exosomes in the pathogenesis of Hashimoto's thyroiditis, positioning them as promising new diagnostic biomarkers and therapeutic targets. The research deta...
